Aflibercept for AMD decreases exudation, does not improve VA

Eylea decreased exudation in a majority of patients with age-related macular degeneration previously treated with Avastin and/or Lucentis; however, visual acuity did not improve, according to study results.The retrospective study included 67 eyes of 63 patients with exudative AMD who were treated with Eylea (aflibercept, Regeneron) for persistent exudation after having received at least three injections of Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech).